Trials / Completed
CompletedNCT01673867
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC
An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 582 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to compare the overall survival of BMS-936558 (Nivolumab) as compared with Docetaxel in subjects with non-squamous cell non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy
Detailed description
CheckMate 057: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 057
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Nivolumab | |
| DRUG | Docetaxel |
Timeline
- Start date
- 2012-11-02
- Primary completion
- 2015-02-05
- Completion
- 2021-12-17
- First posted
- 2012-08-28
- Last updated
- 2023-02-08
- Results posted
- 2016-02-26
Locations
119 sites across 22 countries: United States, Argentina, Australia, Austria, Brazil, Canada, Chile, Czechia, France, Germany, Hong Kong, Hungary, Italy, Mexico, Norway, Peru, Poland, Romania, Russia, Singapore, Spain, Switzerland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01673867. Inclusion in this directory is not an endorsement.